Press Releases

 
Press Releases
  Date Title and Summary View
Dec 28, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1 mg / 0.05 mg. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Zovia® 1/50E-...
Dec 27, 2016
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Dec. 27, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the results of the HERITAGE study have been published in the Journal of the American Medical Association (JAMA). Study results confirm the efficacy, safety and ...
Dec 16, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the launch of the authorized generic for EpiPen® (epinephrine injection, USP) Auto-Injector at a wholesale acquisition cost (WAC) of $300 per epinephrine injection, USP two-pack, which is more than 50% lower than the WAC of EpiPe...
Dec 1, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing World AIDS Day. Observed every Dec. 1, the occasion represents an opportunity to support people living with HIV/AIDS and to remember the approximately 35 million who have died from AIDS-related illnesses si...
Nov 28, 2016
HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company has signed an agreement with the Medicines Patent Pool (MPP) to expand access to chronic hepatitis C medicines in developing countries. The agreement licenses Mylan to produce and market a generic version of Bri...
Nov 10, 2016
Nov 9, 2016
HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2016. Third Quarter 2016 Financial Highlights Total revenues and adjusted total revenues of $3.06 billion, each up 13% compared to the pri...
Nov 8, 2016
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 8, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced submission of Mylan's biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, to the U.S. Food and Drug Administration (FDA) through the 35...
Nov 3, 2016
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for insulin glargine, a long-acting insulin analog use...
Nov 2, 2016
CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Nov. 2, 2016 /PRNewswire/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL), today announced that dosing has begun in a Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834, a proposed biosimilar of ORENCIA (abatacept), to US- an...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase